Thiogenesis Therapeutics, Corp. (Q8M.F)
- Previous Close
0.4100 - Open
0.3840 - Bid 0.3900 x --
- Ask 0.4500 x --
- Day's Range
0.3840 - 0.3840 - 52 Week Range
0.3220 - 0.5000 - Volume
2,000 - Avg. Volume
5,435 - Market Cap (intraday)
19.157M - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0600 - Earnings Date May 22, 2025 - May 26, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Thiogenesis Therapeutics, Corp., a biopharmaceutical company, develops thiol-active therapeutic compounds to treat unmet pediatric medical needs. The company's lead product candidate comprises TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke, other mitochondrial diseases, Rett syndrome, and pediatric non-alcoholic fatty liver diseases. Thiogenesis Therapeutics, Corp. is headquartered in Toronto, Canada.
www.thiogenesis.comRecent News: Q8M.F
View MorePerformance Overview: Q8M.F
Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: Q8M.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: Q8M.F
View MoreValuation Measures
Market Cap
19.75M
Enterprise Value
17.09M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
6.66
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-69.09%
Return on Equity (ttm)
-108.88%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-4.09M
Diluted EPS (ttm)
-0.0600
Balance Sheet and Cash Flow
Total Cash (mrq)
4.15M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.73M